KRYS News and Press, Krystal Biotech Inc. From 11/29/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Krystal Biotech (NASDAQ: KRYS ) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial. Source: Bukhta Yurii / Shutterstock.com The clinical trial behind today’...

Gainers: Krystal Biotech (NASDAQ:KRYS) +118%, Petros Pharmaceuticals (NASDAQ:PTPI) +96%, Adagio Therapeutics (NASDAQ:ADGI) +69%, iSpecimen (NASDAQ:ISPC) +50%, cbdMD (NYSE:YCBD) +31%. Losers: Fennec Pharmaceuticals (NASDAQ:FENC) -51%,...

Announcing topline data from its pivotal GEM-3 trial for its experimental therapy, VYJUVEK dystrophic Epidermolysis Bullosa (dystrophic EB), Krystal Biotech (NASDAQ:KRYS) said the study met the primary endpoint with statistical significance. In reaction, shares of Krystal Biotech (KRYS) ...

•  Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints VYJUVEK TM was well tolerated, with no drug-related serious adverse events ...

Pre-clincal program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in mice KB303 holds potential to be the first-ever directed approach to increase production of elastin in the skin PITTSBURGH, Nov. 19, 2021 (GLOBE NE...

Krystal Biotech is a pivotal-stage gene therapy company that leverages its novel, re-dosable HSV-vectored gene therapy for serious rare diseases. Top-line phase 3 results of their lead candidate, B-VEC, in dystrophic epidermolysis bullosa (DEB) is expected in Q4, 2021. Some reader...

–  Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 –  Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat aesthetic skin conditions is complete –  Strong balanc...

Topline results anticipated in the fourth quarter of 2021 Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint assessment visits PITTSBURGH, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Krystal Bi...

PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a re...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...